Enveda Raises $311M for AI Drug Discovery

Enveda Biosciences has successfully closed a substantial $311 million Series E funding round, signaling strong investor confidence in its AI-powered approach to identifying novel therapeutics. The financing was spearheaded by Catalio Capital Management, with significant participation from a robust syndicate of new and existing backers.

The impressive capital infusion underscores the growing momentum behind biotechnology firms leveraging artificial intelligence to accelerate the drug discovery process. This latest funding brings Enveda's total capital raised to over $845 million, providing ample resources to propel its diverse pipeline through critical clinical development stages and further enhance its proprietary platform, PRISM. The company's strategy centers on deciphering the complex chemistry of life to uncover new medicinal compounds.

New investors joining the round include Durable Capital Partners, ICONIQ, Lightspeed, Surveyor Capital (a Citadel company), T. Rowe Price Investment Management, Digitalis Ventures, a prominent Sovereign Wealth Fund, and Alderline Group. These firms join a strong base of existing supporters, including Baillie Gifford, Premji Invest, FPV Ventures, True Ventures, Kinnevik, Dimension, Lifeforce Capital, and Lux Capital, all of whom continue to back Enveda's innovative vision.

The timing of this funding coincides with encouraging early clinical results reported in 2026 for Enveda's drug candidates targeting atopic dermatitis and metabolic health conditions. These positive outcomes, derived from medicines discovered using the PRISM platform, validate the company's technology and its potential to deliver impactful treatments. The substantial capital will be instrumental in advancing these programs and exploring new therapeutic areas.

As part of the financing agreement, George Petrocheilos, Co-Founder and Managing Partner at Catalio Capital Management, has been appointed to Enveda's Board of Directors. His expertise is expected to be invaluable as the company navigates its next phase of growth and clinical advancement. The biotechnology sector, particularly the AI-driven drug discovery segment, has seen significant investment activity, with companies demonstrating the ability to shorten discovery timelines and identify novel targets attracting substantial capital.

Enveda's unique methodology, which analyzes vast biological datasets to identify natural compounds with therapeutic potential, positions it at the forefront of a paradigm shift in pharmaceutical research. The company's ability to translate complex biological chemistry into viable drug candidates is a key differentiator in a highly competitive market. This Series E round provides the financial runway necessary to translate this potential into tangible clinical successes and further solidify its position as a leader in the field.